Baxter International Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
4.8
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
BAX
Consensus analyst target of $22.12 is 29% above current price.
⚠ currently unprofitable (-10% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $22.12 (+28.5%)
13 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
BAX
JNJ
—
Trailing P/E
26.3×
8.5×
Forward P/E
17.9×
-9.7%
Profit Margin
21.8%
34.6%
Gross Margin
68.0%
—
ROE
26.4%
2.9%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
0.62
Beta
0.33
—
Price / Book
—
$8.9B
Market Cap
$546.9B
$16 – $33
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →